Hansa Biopharma AB

Year-end report 2013

Wed, Feb 05, 2014 09:05 CET

The year in brief · Successfully completed Phase I study with IdeS. The results from the study demonstrate that IdeS is efficacious and well tolerated with a favorable safety profile. · Hansa Medical receives SEK 3.4 million grant from VINNOVA to carry out Phase II study with IdeS · Hansa Medical and Axis-Shield report most promising results from pivotal clinical trial with HBP-analysis · Net sales for the Group amounted to SEK 1.8 (2.6) M · The Group’s results amounted to SEK -17.6 (-16.5) M · Operating income for the Group amounted to SEK -17.6 (-16.8) M · Earnings

Succesfully completed Phase I study with IdeS

Mon, Jan 27, 2014 13:10 CET

The results from the study demonstrate that IdeS is efficacious and well tolerated with a favorable safety profile. IdeS cleaves IgG antibodies efficiently and no intact IgG is detectable in the circulation of healthy subjects within minutes after dosing. The results from the Phase I study are very encouraging and Hansa Medical will file a Phase II study application at the Swedish Medical Products Agency during the first quarter of 2014.”The Phase I trial demonstrates that IdeS is safe, fast and efficacious at the tested dose levels. For a new desensitization protocol, these are exactly the

Contacts

Year-end report 2013

Succesfully completed Phase I study with IdeS

Subscribe

Media

Share

Contacts

Year-end report 2013

Succesfully completed Phase I study with IdeS

Subscribe

Media